Compare Heron Therapeutics Inc (HRTX) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Lumen Technologies Inc — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while Lumen Technologies Inc trades at $6.31 (market cap $6.58B). The key difference: Lumen Technologies Inc is far larger — about 107× Heron Therapeutics Inc's market cap, and Lumen Technologies Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | LUMN | |
|---|---|---|
Market Cap | $61.47M | $6.58B |
Sector | Health | Media |
52-Week High | $1.49 | $11.83 |
52-Week Low | $0.32 | $3.95 |
Enterprise Value | $168.21M | $18.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.
The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.
LUMN trades at $6.33, down 4.67% today, with a bearish technical signal and neutral oscillators. Revenue declined to $12.40B in 2025, with a net loss of $1.74B, though Q2 2026 earnings beat estimates. The company is shifting to digital services, with strategic revenues growing 14.1% in Q2 2026. High debt of $17.49B remains a concern, but positive cash flow from operations of $4.74B in 2025 supports liquidity.
Outlook is mixed: analyst consensus price target is $7.67 with a hold-heavy rating, indicating cautious optimism. Risks include persistent revenue declines and heavy debt load, but opportunities lie in digital transformation and AI-driven growth. CEO share purchases and institutional holdings suggest insider confidence amid challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
